At this year’s conference, pharmaphorum editor-in-chief Jonah Comstock caught up with Catherine Owen Adams, the CEO of Acadia ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

In his first speech since being appointed Health and Human Services Secretary, Robert F Kennedy Jr pledged to investigate the ...

The 2nd ADC Payload Summit (May 6-8 | Boston, MA). This is the first and only conference exclusively focusing on ADC payloads, helping you to reimagine the medicinal chemistry of traditional cytotoxic ...

The 3rd Obesity & Weight Loss Drug Development Summit is the place to be for experts in weight loss drug development tackling ...

A digital therapeutic (DTx) for attention deficit hyperactivity disorder (ADHD) developed by Akili has been approved in Japan ...

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...